Education
About Us
Working with TipRanks
Follow Us
Control Bionics Ltd. (AU:CBL)
ASX:CBL
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.09
Previous CloseN/A
Volume65.91K
Average Volume (3M)173.99K
Market Cap
AU$23.07M
Enterprise ValueAU$18.68M
Total Cash (Recent Filing)AU$672.66K
Total Debt (Recent Filing)AU$435.40K
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Feb 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding411,961,880
10 Day Avg. Volume327,267
30 Day Avg. Volume173,987
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.44
Price to Sales (P/S)1.29
P/FCF Ratio-1.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Assistive-technology NicheControl Bionics operates in a narrow, mission-driven assistive-technology niche serving users with severe speech and physical disabilities. This focused product-market fit supports durable customer stickiness, clinical adoption cycles, and differentiated IP/software integration that can sustain revenue relationships over multiple quarters.
Consistent Revenue GrowthThe company shows recurring top-line expansion, with revenue growth above mid-teens in the latest year. Sustained revenue increases indicate improving market adoption and provide a foundation to leverage fixed costs, pursue margin improvement, and fund incremental R&D or commercialization activities over the medium term.
Conservative Balance Sheet LeverageLow leverage and a strong equity base give the company financial flexibility amid operating losses. Conservative debt levels reduce near-term insolvency risk, preserve strategic optionality for product development or partnerships, and extend runway while management works to convert growth into sustainable profits.
Bears Say
Persistent Unprofitable OperationsDespite revenue growth, the company reports recurring negative net and EBIT margins. Persistent operating losses limit internal reinvestment capacity, increase dependence on external capital, and strain the business model's path to durable profitability unless structural cost or pricing improvements occur over the next several quarters.
Negative Operating Cash Flow And Declining FCFNegative operating cash flow and shrinking free cash flow indicate the business is not converting revenue into liquid resources. This creates ongoing liquidity risk, constrains funding for commercialization and R&D, and increases the likelihood of equity or debt raises that could dilute stakeholders or add financing costs.
Negative Return On EquityA negative ROE signals the company is not generating returns on shareholder capital. Over time, sustained negative ROE undermines capital efficiency, complicates investor expectations for recovery, and raises the pressure to either materially improve operational performance or seek external financing that may affect long-term ownership structure.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.09 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$23.07M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Feb 25, 2026 which is in 8 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Aug 28, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 411,961,880 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.29%
12-Months-Change
Fundamentals
Return on Equity
-103.74%
Trailing 12-Months
Asset Growth
-8.80%
Trailing 12-Months
Company Description
Control Bionics Ltd.
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.
Technical Analysis
Uscom Limited
―
HeraMED Ltd.
―
Atomo Diagnostics Ltd.
―
Adherium Ltd.
―
InhaleRx Limited
―
Options Prices
Currently, No data available
---